Tesaro Builds its Warchest

Kleiner Perkins leads a massive $100M Series B round at Tesaro.  Now, Tesaro not only has the funds to push forward with Phase III trials for lead drug Rolapitant, but they'll likely be an active player in the licensing market as they look to build out their pipeline.  Not bad for a company that's barely a year old...